Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
SAN RAMON, Calif., Sept. 20, 2016 -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that Jonathan Rigby, President and Chief Executive Officer, will present at the Annual Ladenburg Thalmann Healthcare Conference, being held on September 27, 2016 at The Sofitel, in New York City. During the presentation, Mr. Rigby will provide an overview and update on the company's business.
Date: Tuesday, September 27, 2016
Time: 9:30 AM ET
A live audio webcast and archive of the presentation will be available through the Events and Presentations page of the company's corporate website (www.steadymed.com).
About SteadyMed
SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent®, a development stage drug product that combines SteadyMed's PatchPump® technology with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension (PAH). SteadyMed intends to commercialize Trevyent in the U.S. and has signed an exclusive license and supply agreement with Cardiome Pharma Corp. for the commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For additional information about SteadyMed please visit www.steadymed.com.
Marylyn Rigby Senior Director, Investor Relations and Marketing 925-272-4999 [email protected] The Ruth Group David Burke (646) 536-7009 [email protected]
